Figure 2
Figure 2. Treatment responses to pomalidomide in patients with RRMM. (A) ITT population (N = 38). (B) Dual lenalidomide and bortezomib–refractory patients (N = 24).

Treatment responses to pomalidomide in patients with RRMM. (A) ITT population (N = 38). (B) Dual lenalidomide and bortezomib–refractory patients (N = 24).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal